GlassScriptPhysician profile
Sagar Patel
NPI 1841653078
$5,102.32
in general payments reported to CMS, 2019-2025
32 companies · $1,150 in 2025
The $1,150 reported for 2025 was more than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16.39 · 2020: $454 · 2021: $472 · 2022: $841 · 2023: $601 · 2024: $1,566 · 2025: $1,150.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,318.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,317.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $829.83 | 2020-2025 | Farxiga, Brilinta |
| Abbott Laboratories | $742.43 | 2020-2022 | |
| Shockwave Medical, INC | $651.44 | 2023-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Medtronic, INC. | $646.92 | 2022-2025 | Ffrangio, Symplicity G3, Onyx Frontier |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $259.78 | 2023-2025 | Lifevest |
| Becton, Dickinson and Company | $245.04 | 2024 | Bard 3dmax Mesh, Phasix Mesh |
| Abiomed | $188.16 | 2024-2025 | Impella |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.08 | 2021-2025 | Jardiance |
| Boston Scientific Corporation | $165.75 | 2023-2024 | Eluvia, Watchman Flx |
| Novo Nordisk INC | $158.28 | 2024-2025 | Wegovy, Ozempic, Rybelsus |
| Davol INC. | $150.00 | 2025 | Phasix Mesh |
| Lilly USA, LLC | $140.41 | 2023-2025 | Mounjaro, Zepbound |
| Pfizer INC. | $103.41 | 2019-2025 | |
| Atricure, INC. | $77.10 | 2022 | |
| Getinge USA Sales, LLC | $71.63 | 2023 | Cardiohelp |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $54.04 | 2025 | Onpattro |
| Endologix LLC | $49.37 | 2025 | Torus Stent Graft System, Endocross Device |
| Terumo Medical Corporation | $46.81 | 2022-2024 | Metacross Otw |
| Kiniksa Pharmaceuticals International, Plc | $43.51 | 2024 | Arcalyst |
| Cvrx, INC. | $33.40 | 2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $31.41 | 2024 | Verquvo |
| Amgen INC. | $29.49 | 2020-2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $29.20 | 2024 | Eliquis |
| Edwards Lifesciences Corporation | $20.11 | 2024 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Penumbra, INC. | $18.54 | 2024 | Indigo System |
| Scpharmaceuticals INC. | $18.16 | 2024 | |
| Biotronik INC. | $17.66 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $15.54 | 2023 | Inpefa |
| Janssen Pharmaceuticals, INC | $15.44 | 2024 | Xarelto |
| Angiodynamics, INC. | $14.95 | 2024 | Auryon Laser System 100-120 Vac |
| Kiniksa Pharmaceuticals, LTD. | $14.64 | 2023 | Arcalyst |
| Azurity Pharmaceuticals, INC. | $14.21 | 2024 | Edarbi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sagar Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.